|
1
|
Regezi JA, Sciubba JJ and Jordan RC: Oral
Pathology: Clinical Pathologic Correlations. 6th. Elsevier Health
Sciences; St. Louis, MO: 2012
|
|
2
|
Lookingbill DP, Spangler N and Sexton FM:
Sexton: Skin involvement as the presenting sign of internal
carcinoma. A retrospective study of 7316 cancer patients. J Am Acad
Dermatol. 22:19–26. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yin XM: Signal transduction mediated by
Bid, a pro-death Bcl-2 family proteins, connects the death receptor
and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petti S and Scully C: Oral cancer
knowledge and awareness: primary and secondary effects of an
information leaflet. Oral Oncol. 43:408–415. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu D, He J, Yuan Z, et al: EGFR
expression correlates with decreased disease-free survival in
triple-negative breast cancer: a retrospective analysis based on a
tissue microarray. Med Oncol. 29:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saxena R, Chandra V, Manohar M, et al:
Chemotherapeutic Potential of
2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen
Receptor- Negative Breast Cancer Cells: Action via Prevention of
EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and
MEK/Erk/AP-1 Pathways. PLoS One. 8:e662462013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen Q, Uray IP, Li Y, et al: Targeting
the activator protein 1 transcription factor for the prevention of
estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila).
1:45–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Zhang H, Chen Y, Fan L and Fang J:
Forkhead transcription factor FOXO3a protein activates nuclear
factor kappaB through B-cell lymphoma/leukemia 10 (BCL10) protein
and promotes tumor cell survival in serum deprivation. J Biol Chem.
287:17737–17745. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang C, Song X, Li Y, et al: Low-Dose
Paclitaxel Ameliorates Pulmonary Fibrosis by Suppressing
TGF-beta1/Smad3 Pathway via miR-140 Upregulation. PLoS One.
8:e707252013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H, Duan ZW, Xie P, et al: Effects of
paclitaxel on EGFR endocytic trafficking revealed using quantum dot
tracking in single cells. PLoS One. 7:e454652012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo YH, Gao FH, Shi J, Yuan HH and Jiang
B: [EGFR-ERK signaling pathway down-regulates miRNA-145 in lung
cancer cells]. Zhonghua Zhong Liu Za Zhi. 35:187–192. 2013.(In
Chinese). PubMed/NCBI
|
|
14
|
Soares AS, Costa VM, Diniz C and Fresco P:
Potentiation of cytotoxicity of paclitaxel in combination with
Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible
therapeutic strategy for melanoma. Biomed Pharmacother. 67:777–789.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meloche S and Pouysségur J: The ERK1/2
mitogen-activated protein kinase pathway as a master regulator of
the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li MS, Li PF, Chen Q, Du GG and Li G:
Alpha-fetoprotein stimulated the expression of some oncogenes in
human hepatocellular carcinoma Bel 7402 cells. World J
Gastroenterol. 10:819–824. 2004.PubMed/NCBI
|
|
18
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K
and Tamaki T: Antioxidants inhibit JNK and p38 MAPK activation but
not ERK 1/2 activation by angiotensin II in rat aortic smooth
muscle cells. Hypertens Res. 24:251–261. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
PaezPereda M, Kuchenbauer F, Arzt E and
Stalla GK: Regulation of pituitary hormones and cell proliferation
by components of the extracellular matrix. Braz J Med Biol Res.
38:1487–1494. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Connell RM and Baltimore D: MicroRNAs
and hematopoietic cell development. Curr Top Dev Biol. 99:145–174.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pick A and Wiese M: Tyrosine kinase
inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP
cells via the PI3 K/Akt signaling pathway. Chem Med Chem.
7:650–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee DH, Szczepanski MJ and Lee YJ:
Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt
signaling pathway in human prostate cancer cells. J Cell Biochem.
106:1113–1122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lowe VJ, Booya F, Fletcher JG, et al:
Comparison of positron emission tomography, computed tomography,
and endoscopic ultrasound in the initial staging of patients with
esophageal cancer. Mol Imaging Biol. 7:422–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
SchwarzDose J, Untch M, Tiling R, et al:
Monitoring primary systemic therapy of large and locally advanced
breast cancer by using sequential positron emission tomography
imaging with [18F] fluorodeoxyglucose. J Clin Oncol.
27:535–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
